These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 24734285)

  • 1. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
    Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
    Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal allergen-neutralizing IgG
    Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
    J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
    Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
    Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
    Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
    EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis.
    Eguiluz-Gracia I; Parkin RV; Layhadi JA; Palmer E; Meng X; Zhu R; Sahiner U; Durham SR; Torres MJ; Mayorga C; Rondon C; Shamji MH
    Allergy; 2024 Aug; 79(8):2197-2206. PubMed ID: 38483174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
    Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
    Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy.
    Shamji MH; Larson D; Eifan A; Scadding GW; Qin T; Lawson K; Sever ML; Macfarlane E; Layhadi JA; Würtzen PA; Parkin RV; Sanda S; Harris KM; Nepom GT; Togias A; Durham SR
    J Allergy Clin Immunol; 2021 Oct; 148(4):1061-1071.e11. PubMed ID: 33819508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of IgE-Allergen-CD23 Complex Changes in Children Treated with Subcutaneous Immunotherapy for Japanese Cedar Pollinosis.
    Asaumi T; Sato S; Yanagida N; Matsuhara H; Kobayashi S; Fukano C; Ohashi-Doi K; Ebisawa M
    Int Arch Allergy Immunol; 2021; 182(3):190-194. PubMed ID: 33032294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study.
    Zidarn M; Košnik M; Šilar M; Bajrović N; Korošec P
    Allergy; 2015 May; 70(5):547-55. PubMed ID: 25627309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
    Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
    Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
    Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
    Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
    Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
    Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.